Key facts
- It has raised $2.1M; the latest was Early Stage VC ($2.1M) in Mar 2026.
- Notable investors include Innovation Authority, NGT HealthCare II.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kailo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Kailo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kailo Pharma
Operator of a peptide-based therapeutic platform intended to target and reduce the amplification of traumatic memories in the brain. The company offers a nasal delivery approach that directly acts on memory-related neural mechanisms, enabling individuals with trauma-related disorders to manage persistent symptoms through targeted intervention.
- Sector
- Healthcare
- HQ
- Nazareth, Israel
- Founded
- 2026
- Ownership
- Privately Held (backing)
Kailo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kailo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kailo Pharma in its N-PORT filings yet. We sweep new filings monthly.